Longevity of the placebo effect in the therapeutic angiogenesis and laser myocardial revascularization trials in patients with coronary heart disease.
The long-term beneficial effects of placebo therapy were evaluated in angiogenesis and laser myocardial revascularization trials in patients who had end-stage coronary heart disease. Improvements in mean angina class, exercise treadmill time, and quality of life were mostly maintained at 30 +/- 6 months of follow-up. Persistence of effect cannot be used as evidence of efficacy, and double-blinded trials are essential in this patient population.
Rana
Jamal S
JS
Angiogenesis Research Center and Division of Cardiology and Cardiac Surgery, Department of Medicine, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.
Mannam
Arjuna
A
Donnell-Fink
Laurel
L
Gervino
Ernesto V
EV
Sellke
Frank W
FW
Laham
Roger J
RJ
D000368:Aged; D016342:Angioplasty, Laser; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D003327:Coronary Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery*; D004311:Double-Blind Method; D005080:Exercise Test; D017079:Exercise Tolerance / Q000502:physiology; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D009204:Myocardial Revascularization / Q000379:methods*; D015990:Placebo Effect; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D011994:Recombinant Proteins / Q000627:therapeutic use; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
D000925:Anticoagulants; D011994:Recombinant Proteins; D016222:Fibroblast Growth Factor 2; D006493:Heparin